Molecular targets as therapeutic strategies in the management of breast cancer.
Molecular targets as therapeutic strategies in the management of breast cancer.
复制标题
DOI：
10.1053/srao.2002.35253
复制
发表时间：
2002-10
影响因子：
3.5
通讯作者：
Carolyn I. Sartor
中科院分区：
文献类型：
--
作者：
Carolyn I. Sartor
针对特定生物靶点的治疗长期以来一直用于乳腺癌的治疗;雌激素受体是一种经过验证的预后和治疗靶点，抗雌激素治疗已有效使用数十年。近年来，随着科学的进步和对乳腺癌发病机制的深入了解，潜在的分子靶点和新的治疗药物不断涌现。曲妥珠单抗（Herceptin，Genentech，South San弗朗西斯科，CA）（一种抗HER 2抗体）的成功刺激了其他生物定向治疗剂的开发。在这篇综述中，我讨论了与乳腺癌相关的三个靶点（表皮生长因子受体家族、血管生成和NF-κ B），并讨论了针对这些靶点的治疗方法。
Therapy directed against specific biologic targets has long been used in the treatment of breast cancer; the estrogen receptor is a validated prognostic and therapeutic target, and antiestrogen therapy has been used effectively for decades. Recently, scientific progress and increased comprehension of mechanisms of breast cancer pathogenesis have led to the proliferation of both potential molecular targets and new therapeutic agents. The success of traztuzumab (Herceptin, Genentech, South San Francisco, CA), an anti-HER2 antibody, has spurred the development of other biologically directed therapeutics. In this overview, I discuss three targets relevant to breast cancer (the epidermal growth factor receptor family, angiogenesis, and NF-kappa B), and therapeutic approaches directed against these targets are discussed.